India-based Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders.

Suven Life Sciences Ltd. Annual stock financials by MarketWatch. View the latest SUVEN financial statements, income statements and financial ratios.

Suven Life Sciences Ltd. is a biopharmaceutical company. It focuses on discovering, developing and commercializing novel pharmaceutical products, which ...

Indian contract drug manufacturer Suven Pharmaceuticals said on Thursday it will merge with Cohance Lifesciences in an all-share deal, as it looks to further scale up its contract and development ...

Suven Pharma to merge with Cohance Lifesciences Upon the scheme becoming effective, all shareholders of Cohance will be issued 11 shares of Suven for every 295 shares held in the former, Suven ...

Advent merges Cohance and Suven The merged entity will have three distinct business units – Pharma CDMO, Spec Chem CDMO, and API+, inclusive of formulations ...

Advent International Corp., one of the world’s largest private equity firms, will purchase a controlling stake in India’s Suven Pharmaceuticals Ltd. for at least 63.13 billion rupees ($762 ...

Private equity major Advent International will buy a "significant" stake in Suven Pharmaceuticals Ltd from its promoter Jasti family and consider merging it with a peer in its portfolio, the ...

Suven Pharmaceuticals Ltd. Door No. 8-2-334, 3rd Floor SDE Serene Chambers, Road No.5 Avenue 7, Banjara Hills Hyderabad, TS 500034 Phone91 40 235-49414 IndustryPharmaceuticals SectorHealth Care ...

Looking to the future, Suven’s Horizon 2 initiative – which includes plans to incorporate capabilities in flow chemistry, messenger ribonucleic acid (mRNA), and peptides by fiscal year 2030 ...